21 May 2013
Keywords: halozyme/baxter, sign, eu, hylenex, deal, health, care
Article | 15 August 2005
US health care giant Baxter has exercised its option to market, sell and distribute Halozyme's human recombinant hyaluronidase, Hylenex
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
15 August 2005
22 August 2005
20 May 2013
© 2013 thepharmaletter.com